SolidSEQ Endometrial Cancer Panel [31] Test
About SolidSEQ Endometrial Cancer Panel [31] Test
| Field | Value |
|---|---|
| Also Known As | Endometrial Cancer NGS Panel, EC 31-Gene Panel, Uterine Cancer Molecular Panel, Endometrial Cancer Prognostication Panel |
| Sample Type | Paraffin-Embedded Tissue Block (FFPE tumour tissue from biopsy or surgical specimen) |
| Fasting Required | No — this is a tissue-based test, not a blood test |
| Report Time | 21 Days |
| Recommended For | Women diagnosed with endometrial (uterine) cancer; post-menopausal women aged 55 to 65 years; younger women with suspected hereditary cancer risk |
| Price | Starting at ₹34,000 |
What is a SolidSEQ Endometrial Cancer Panel [31] Test?
The SolidSEQ endometrial cancer panel [31] test is an advanced molecular test that analyses 31 genes linked to endometrial (uterine) cancer. It uses next-generation sequencing (NGS), a technology that reads the genetic code of tumour tissue in great detail. The test is typically ordered by an oncologist after a diagnosis of endometrial cancer to understand the tumour's molecular profile and guide treatment decisions. It requires a preserved tumour tissue sample, called an FFPE block, from a previous biopsy or surgery.
What Does a SolidSEQ Endometrial Cancer Panel [31] Test Measure?
This panel examines specific gene mutations and molecular markers within tumour tissue. Each finding helps classify the cancer into a subtype with distinct prognosis and treatment implications.
The key genes and markers assessed by this panel include the following:
| Gene / Marker | What it Detects |
|---|---|
| POLE | Exonuclease domain mutations linked to excellent prognosis |
| TP53 | Mutations associated with aggressive tumour behaviour |
| MLH1, MSH2, MSH6, PMS2 (MMR genes) | Mismatch repair deficiency; also screens for Lynch syndrome |
| PTEN | Tumour suppressor gene alterations, common in endometrioid cancer |
| PIK3CA | Mutations in cell growth pathways |
| BRCA1 / BRCA2 | Hereditary cancer risk markers |
| NTRK1, NTRK2, NTRK3 | Gene fusions that may be targeted by specific therapies |
| BRAF, RET | Alterations potentially responsive to targeted treatment |
| KRAS, CTNNB1, ARID1A, FBXW7, PPP2R1A | Additional genes that help classify tumour type |
| Microsatellite Instability (MSI) status | Genetic instability caused by defective DNA repair |
Why is a SolidSEQ Endometrial Cancer Panel [31] Test Done?
This test is ordered when a patient has been diagnosed with endometrial cancer and the treating oncologist needs detailed molecular information to plan the best course of care.
Common Symptoms That May Require This Test
The following symptoms often prompt investigation for endometrial cancer, after which this panel may be ordered:
- Vaginal bleeding or spotting after menopause
- Abnormal vaginal bleeding between periods before menopause
- Unusually heavy, prolonged, or frequent vaginal bleeding in women over 40
- Lower abdominal pain or pelvic cramping
- Thin, white, or clear vaginal discharge in post-menopausal women
Conditions This Test Can Help Detect
This panel helps identify or classify the following conditions:
- The four molecular subtypes of endometrial cancer: POLE ultra-mutated, MSI-H (microsatellite instability-high), copy-number low, and copy-number high
- Lynch syndrome, caused by inherited mutations in mismatch repair genes, which significantly raises the lifetime risk of endometrial cancer
- Other hereditary cancer syndromes, including those linked to BRCA1/2, Cowden syndrome, and Li-Fraumeni syndrome
- Recurrent or advanced endometrial cancer requiring targeted therapy decisions
How to Prepare and What to Expect
The SolidSEQ endometrial cancer panel [31] test procedure does not require a new biopsy or blood draw in most cases. Your oncologist will arrange for existing tumour tissue to be used.
Do You Need to Fast?
No fasting is required. This test uses preserved tumour tissue, not a blood or urine sample.
Practical Tips Before Your Test
Keep the following points in mind before submitting your sample:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test
- Ensure that the FFPE tissue block contains at least 20% tumour content; your oncologist or pathologist will verify this
- Arrange for the histopathology (HPE) report and immunohistochemistry (IHC) report to accompany the tissue block
- Inform your oncologist if you have received prior chemotherapy or radiation, as this may affect the tissue sample quality
- Confirm that the tissue was fixed in 10% neutral buffered formalin, as other fixatives may affect the quality of results
Step-by-Step Procedure
The following steps outline how the SolidSEQ endometrial cancer panel [31] test is processed:
- Tumour tissue is sourced from a previously performed biopsy (such as an endometrial biopsy or dilation and curettage) or from a surgical specimen (such as a hysterectomy).
- The tissue block, preserved in paraffin wax (FFPE format), is packaged and dispatched to the laboratory at room temperature (18 to 28 degrees Celsius).
- Laboratory scientists cut thin sections from the FFPE block and extract DNA from the tumour cells.
- The extracted DNA is prepared and loaded onto next-generation sequencing instruments.
- The NGS platform reads the genetic code across all 31 genes in the panel and identifies any mutations or alterations.
- A specialist reviews the sequencing data and generates a detailed molecular report, which is sent to your oncologist within 21 days.
Factors That Can Affect Accuracy
The following factors may influence the reliability of results:
- Low tumour content in the tissue sample (less than 20% may yield unreliable results)
- Poor or incorrect tissue fixation during sample preparation
- Age of the tissue block (older samples may have degraded DNA)
- Prior chemotherapy or radiation treatment, which can alter the tumour's genetic profile
- Sample handling or storage issues during transit
Understanding Your SolidSEQ Endometrial Cancer Panel [31] Results
Results from this test are reported as mutation status rather than numerical values. Your oncologist will interpret the findings in the context of your full clinical picture.
| Parameter | Possible Results | Clinical Significance |
|---|---|---|
| POLE mutation | Detected / Not detected | Detected = excellent prognosis across all disease stages |
| MSI status | MSI-High / Microsatellite Stable | MSI-High = may respond well to immunotherapy |
| MMR protein status | Deficient (dMMR) / Proficient (pMMR) | dMMR = immunotherapy candidate; possible Lynch syndrome |
| TP53 mutation | Detected / Not detected | Detected = associated with aggressive disease and poorer prognosis |
| Molecular subtype | POLE-mutated / MSI-H / Copy Number Low / Copy Number High | Determines prognosis and guides treatment planning |
These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Prior cancer treatment and sample quality can affect how results are read:
- Prior chemotherapy or radiation therapy may alter the tumour's genetic profile, making some mutations harder to detect.
- If tumour content in the sample is below 20%, results may be inconclusive or unreliable, and repeat testing with a new sample may be needed.
- Older FFPE blocks with degraded DNA may limit the depth and accuracy of sequencing.
How to Maintain Healthy Levels
Given the nature of this test, the following general guidance applies:
- Attend all follow-up appointments with your oncologist as scheduled to monitor treatment response.
- Seek genetic counselling if the results suggest a hereditary cancer syndrome, such as Lynch syndrome or a BRCA-related condition.
- Discuss with your oncologist whether close family members should consider genetic screening based on your results.
Lupin Diagnostics SolidSEQ Endometrial Cancer Panel [31] Price
The SolidSEQ endometrial cancer panel [31] test costs start at ₹34,000 at Lupin Diagnostics. This test requires a visit to a Lupin Diagnostics centre; home collection is not available for this test.
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 34000 |
| Pune | 34000 |
| Bangalore | 34000 |
| Chennai | 34000 |
Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book the SolidSEQ endometrial cancer panel [31] test online or at a centre:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time to submit your FFPE tissue block along with your clinical history and supporting pathology reports.
- Receive your report via email or WhatsApp within 21 days.
Frequently Asked Questions
The SolidSEQ endometrial cancer panel [31] test is a next-generation sequencing test that examines 31 genes in tumour tissue from a patient diagnosed with endometrial cancer. It identifies the cancer's molecular subtype, predicts prognosis, and helps the oncologist decide on targeted therapies or immunotherapy.
This test is recommended for women diagnosed with endometrial (uterine) cancer, particularly those with high-grade, advanced, or recurrent disease. It is also relevant for women with suspected hereditary cancer syndromes such as Lynch syndrome.
No new biopsy or blood draw is usually needed. The test uses an FFPE tumour tissue block preserved from a previous biopsy or surgery. Your oncologist will arrange for this tissue to be packaged and submitted to the laboratory.
The SolidSEQ endometrial cancer panel [31] test has a turnaround time of 21 days. NGS-based panels require detailed laboratory processing, which takes longer than routine blood tests. Your doctor will let you know when to expect your report.
A POLE-mutated result indicates that the tumour belongs to a specific molecular subtype associated with an excellent prognosis, even in higher-grade cases. Your oncologist will use this information to guide decisions about adjuvant treatment.
Yes. If the results show mismatch repair deficiency (dMMR), this may indicate Lynch syndrome, a hereditary condition that raises the lifetime risk of endometrial and other cancers. Further germline (blood-based) genetic testing is typically recommended in such cases.
Yes, the results directly inform treatment decisions. For example, tumours with MSI-High or dMMR status may be eligible for immunotherapy. If NTRK gene fusions are detected, specific targeted therapies may be considered. Your oncologist will discuss all options based on your complete molecular profile.
SolidSEQ Endometrial Cancer Panel [31] Test
